Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial
Evan S. Dellon(University of North Carolina at Chapel Hill), Ikuo Hirano(Northwestern University), Chinyu Su(Pfizer (United States)), Albert J. Bredenoord(Amsterdam Neuroscience), Luc Biedermann(University of Zurich), Fabio Cataldi(Pfizer (United States)), Thai Nguyen-Cleary(Pfizer (United States)), Margaret H. Collins(Cincinnati Children's Hospital Medical Center), Huaming Tan(Pfizer (United States)), Pamela Clax(Pfizer (United States)), Jin Yu(Pfizer (United States)), Wenjin Wang(Pfizer (United States)), Joseph Wu(Pfizer (United States)), John Woolcott(Pfizer (United States)), Márjori Dulcine, Hamish Philpott(The University of Adelaide)
Cited by 15
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
|Gastroenterology|2018|1.1k
Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States
|Gastroenterology|2015|996